Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 52

Results For "RMAT"

1996 News Found

Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome
Biopharma | December 04, 2025

Aelis Farma gets EMA nod for phase 2B trial of AEF0217 in down syndrome

AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor


BPL Medical Technologies unveils critical-care innovations at ISACON 2025
Medical Device | December 04, 2025

BPL Medical Technologies unveils critical-care innovations at ISACON 2025

The company introduced the ExcelSign E12 and E17 modular patient monitors, the Relife 1000 biphasic defibrillator, and a new OT charting software


Promotion of indigenous pharmaceutical manufacturing
Policy | December 04, 2025

Promotion of indigenous pharmaceutical manufacturing

PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore


Celltrion gets Health Canada nod for Eylea biosimilar Eydenzelt
Clinical Trials | December 03, 2025

Celltrion gets Health Canada nod for Eylea biosimilar Eydenzelt

Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data


L&T Technology unveils next-gen AI digital twin for lung diagnostics
Digitisation | December 03, 2025

L&T Technology unveils next-gen AI digital twin for lung diagnostics

The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy


WHO urges rapid expansion of new HIV prevention tools amid funding crisis
Healthcare | December 03, 2025

WHO urges rapid expansion of new HIV prevention tools amid funding crisis

Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN


FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich
Drug Approval | December 02, 2025

FDA accepts Wockhardt's NDA for breakthrough antibiotic Zaynich

This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA


Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers
Clinical Trials | December 02, 2025

Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers

Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM


Lilly slashes prices on Zepbound vials to expanding access to obesity treatment
News | December 02, 2025

Lilly slashes prices on Zepbound vials to expanding access to obesity treatment

Patients can now get the starting 2.5 mg dose for $299 per month